Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12631712 | 0.77 | KMT2A (0.34) | KMT2AALDH1A1LMNA | |
| SCHEMBL19749988 | 0.71 | — | — | |
| SCHEMBL21064227 | 0.71 | — | — | |
| SCHEMBL23280514 | 0.70 | — | — | |
| SCHEMBL19116254 | 0.70 | — | — | |
| SCHEMBL22810901 | 0.67 | KMT2A (0.33) | KMT2A | |
| SCHEMBL22903995 | 0.67 | KMT2A (0.33) | KMT2A | |
| SCHEMBL18947476 | 0.67 | KMT2A (0.33) | KMT2A | |
| SCHEMBL20201427 | 0.65 | ENO1 (0.63) | KMT2A | |
| SCHEMBL19231277 | 0.63 | LMNA (0.37) | KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190134052-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | NOVARTIS AG (CH) | 2019-05-09 | — | — | US | disclosed |
| US-20170049781-A1 | HSP90 INHIBITOR COMBINATIONS | NOVARTIS AG (CH) | 2017-02-23 | — | — | US | disclosed |
| US-20170049781-A1 | HSP90 INHIBITOR COMBINATIONS | NOVARTIS AG (CH) | 2017-02-23 | — | — | US | disclosed |
| US-20160346292-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR | NOVARTIS AG (CH) | 2016-12-01 | — | — | US | disclosed |
| US-20160346292-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR | NOVARTIS AG (CH) | 2016-12-01 | — | — | US | disclosed |
| US-20150209362-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20150209362-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20150141426-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | NOVARTIS PHARMACEUTICALS CORPORATION | 2015-05-21 | — | — | US | disclosed |
| US-20150141426-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | NOVARTIS PHARMACEUTICALS CORPORATION | 2015-05-21 | — | — | US | disclosed |
| EP-2637665-B1 | DEXAMETHASONE COMBINATION THERAPY | UNIV TEXAS (US) | 2015-04-08 | — | — | EP | disclosed |
| US-20070244109-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244109-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-7250443-B2 | Pyrrole based inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250443-B2 | Pyrrole based inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2007-07-31 | — | — | US | disclosed |
| WO-2007084786-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-07-26 | — | — | WO | disclosed |
| US-20070123546-A1 | 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones | CHIRON CORPORATION | 2007-05-31 | — | — | US | disclosed |
| US-20070123546-A1 | 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones | CHIRON CORPORATION | 2007-05-31 | — | — | US | disclosed |
| WO-2007041362-A1 | 2-AMINO-7,8-DIHYDRO-6H-PYRIDO[4,3-D] PYRIMIDIN-5-ONES | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| US-20070027150-A1 | 2-Amino-quinazolin-5-ones | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027150-A1 | 2-Amino-quinazolin-5-ones | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346292-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR | HSP90B1, HSP90AB1, HSP90AB2P | KMT2A 2772/4885ALDH1A1 3038/4885LMNA 4465/4885 |
| US-20150141426-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | PIK3CA, PIK3CD, PIK3R5 | KMT2A 1554/4885ALDH1A1 3308/4885LMNA 4436/4885 |
| US-20070123546-A1 | 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones | TYMP, TPMT, TYMS | KMT2A 2925/4885ALDH1A1 1413/4885LMNA 2108/4885 |
| US-20150209362-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR | HSP90B1, HSP90AB1, HSP90AB2P | KMT2A 2772/4885ALDH1A1 3038/4885LMNA 4465/4885 |
| US-20170049781-A1 | HSP90 INHIBITOR COMBINATIONS | HSP90AB1, HSP90B1, HSP90AA1 | KMT2A 3299/4885ALDH1A1 3574/4885LMNA 3091/4885 |
| US-20190134052-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | PIK3CA, PIK3CD, PIK3R5 | KMT2A 1554/4885ALDH1A1 3308/4885LMNA 4436/4885 |
| US-20070244109-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | GSK3B, GSK3A, PYGB | KMT2A 3535/4885ALDH1A1 3907/4885LMNA 1504/4885 |
| US-20070027150-A1 | 2-Amino-quinazolin-5-ones | TK1, TK2, SLC1A5 | KMT2A 1823/4885ALDH1A1 1718/4885LMNA 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.